Public comments

Page 1 of 1

PUBLIC SUBMISSION

As of: 8/5/20 8:43 AM
Received: August 03, 2020
Status: Posted
Posted: August 05, 2020
Tracking No. 1k4-9i6h-w3iv
Comments Due: August 03, 2020
Submission Type: Web

Docket: CDC-2020-0053
Behavioral Risk Factor Surveillance System (BRFSS) Asthma Call-back Survey (ACBS)
Comment On: CDC-2020-0053-0001
Behavioral Risk Factor Surveillance System (BRFSS) Asthma Call-back Survey (ACBS) 202011803
Document: CDC-2020-0053-0002
Comment from (Anonymous Anonymous)

Submitter Information
Name: Anonymous Anonymous

General Comment
I'm not sure if this is risky behavior, but President Trump is currently spinning around like an
unbalanced top.
First he channeled his inner ostrich, burying his head in the sand and pretending that Covid-19
wasn't spreading like wildfire. Then when his handlers grew concerned that he looked out of
touch, he resumed the Coronavirus press briefings and announced that we had a problem that
would get worse before it got better.
Trump's recognition of the pandeminc lasted one week. Now he is back to contradicting his
experts, saying that both Fauci and Birx have it wrong. And who knows where his wobbly path
will lead? Maybe he'll start replaying his greatest hits, e.g. that this is all a "Democrat hoax"
designed to make him look bad.

https://www.fdms.gov/fdms/getcontent?objectId=09000064847d02ff&format=xml&showor... 8/5/2020

Page 1 of 1

PUBLIC SUBMISSION

As of: 8/5/20 8:44 AM
Received: August 03, 2020
Status: Posted
Posted: August 05, 2020
Tracking No. 1k4-9i6h-yqz7
Comments Due: August 03, 2020
Submission Type: Web

Docket: CDC-2020-0053
Behavioral Risk Factor Surveillance System (BRFSS) Asthma Call-back Survey (ACBS)
Comment On: CDC-2020-0053-0001
Behavioral Risk Factor Surveillance System (BRFSS) Asthma Call-back Survey (ACBS) 202011803
Document: CDC-2020-0053-0003
Comment from (Anonymous Anonymous)

Submitter Information
Name: Anonymous Anonymous
Address: 20004
Email: emma.will@lung.org

General Comment
Please see the attached document for comments from the American Lung Association on the
BRFSS Asthma Call-back Survey.

Attachments
American Lung Association Comments to CDC re BRFSS Asthma Callback Survey

https://www.fdms.gov/fdms/getcontent?objectId=09000064847d05d7&format=xml&showo... 8/5/2020

August 3, 2020
Jeffrey M. Zinger
Information Collection Review Office
Centers for Disease Control and Prevention
1600 Clifton Road NE, MS D-74
Atlanta, Georgia 30329
Re: Behavioral Risk Factor Surveillance System Asthma Call-back Survey
Dear Mr. Zinger:
Thank you for the opportunity to submit comments on the Proposed Data Collection Submitted for
Public Comment and Recommendations (Docket No. CDC-2020-0053) regarding the Behavioral Risk
Factor Surveillance System (BRFSS) Asthma Call-back Survey (ACBS).
The American Lung Association is the oldest voluntary public health association in the United States,
currently representing more than 36 million individuals living with chronic lung disease. An estimated
24.8 million Americans currently have asthma, including 5.5 million children.1
Asthma cannot be cured, but it can be managed effectively through guidelines-based care. Consistent,
comprehensive and regularly updated data on the prevalence of asthma and other key indicators of
asthma control is critical to developing, implementing and evaluating programs and policies to reduce
the burden of asthma. The Lung Association therefore encourages the Centers for Disease Control and
Prevention (CDC) to continue to administer the Asthma Call-back Survey.
Asthma Call-back Survey data provide key information to the CDC’s National Asthma Control Program
(NACP). The NACP tracks asthma prevalence, promotes asthma control and prevention and builds
capacity in state health programs. It has been a highly effective program: while the rate of asthma has
increased, asthma morbidity and mortality rates have decreased due to improved control of the disease
among patients. Comprehensive and consistent data about asthma prevalence, hospitalizations and
measures of asthma control are critical to determine program effectiveness across state asthma
programs supported by the NACP. The Asthma Call-back Survey provides data that help the NACP and
funded states evaluate state asthma programs to determine effectiveness and identify best practices.
Clear outcome metrics ensure that the NACP will continue to provide effective asthma control
interventions across the funded states.
Data from the Asthma Call-back Survey have also informed research featured in several journals, such as
the CDC’s Morbidity and Mortality Weekly Report, Journal of Asthma, Medical Care, the Journal of
Preventive Medicine, and others. As researchers continue to use these valuable data, they can identify
trends related to asthma and help identify areas of innovation or concern in asthma care. Building the
body of research around asthma can help inform evidence-based care and clinical guidelines.

The Lung Association encourages CDC to continue to look for opportunities to improve data collection
on asthma. For example, the latest Asthma Call-back Survey data available for adults are from 2016 and
the most recent data for children are from 2014. Regularly collected, comprehensive data that can be
compared across all 50 states and include asthma prevalence and key measures of asthma control (such
as symptoms, medication use, self-management education and environmental factors) for both adults
and children are critical to the work of the American Lung Association and many other stakeholders
working to help patients with asthma.
The Lung Association encourages CDC to continue to collect the Asthma Call-back Survey data and to
continue to improve the collection of information about asthma so that it is consistent and inclusive
across the United States. Thank you for the opportunity to provide comments.
Sincerely,

Harold P. Wimmer
National President and CEO

1

Centers for Disease Control and Prevention. Most Recent National Asthma Data. Retrieved August 3, 2020.
Available at: https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm

55 West Wacker Drive, Suite 1150 | Chicago, IL 60601 | 1-800-LUNGUSA | Lung.org